Leuprolide depot (a GnRH agonist) may induce ovarian cyst formation via its flare effect; what is the recommended protocol for proceeding with in vitro fertilization (IVF)?

Management of Leuprolide-Induced Ovarian Cysts During IVF

When ovarian cysts develop from leuprolide depot's flare effect, aspirate the cyst under local anesthesia and proceed with ovarian stimulation as scheduled, or alternatively, switch to a luteal-phase long protocol with daily leuprolide to avoid the flare effect entirely.

Understanding the Flare Effect and Cyst Formation

Leuprolide acetate (a GnRH agonist) initially stimulates gonadotropin release before achieving pituitary suppression, causing a transient "flare" in estradiol levels during the first week of treatment 1. This flare effect leads to ovarian cyst formation in approximately 20% of patients, with significantly higher cyst numbers when leuprolide is started during the follicular phase compared to the luteal phase 2.

The mechanism involves initial LH and FSH elevation, which can enlarge pre-existing follicles or corpora lutea into functional cysts 2. These cysts contain follicular fluid with steroid levels similar to normal follicles but are typically acellular and contain no oocytes 2.

Immediate Management Algorithm

If Cysts Are Already Present:

1. Perform ultrasound-guided aspiration under local anesthesia

   • This allows you to proceed with scheduled ovarian stimulation on day 16 after GnRH agonist administration 2
   • Aspiration is safe, well-tolerated, and does not compromise IVF outcomes
   • Critical distinction: Luteal phase cysts are more benign than follicular phase cysts and associated with better IVF success rates after aspiration 2

2. Continue with the planned stimulation protocol after aspiration

   • No need to cancel or delay the cycle
   • Pregnancy rates remain acceptable even after cyst aspiration

If Starting Fresh (Prevention Strategy):

The optimal approach is to initiate leuprolide during the mid-luteal phase (days 21-23) rather than the follicular phase 3, 2. This timing reduces both the incidence and number of cysts per patient.

Protocol Selection to Minimize Cyst Formation

Option 1: Luteal-Phase Long Protocol (Preferred for Cyst Prevention)

• Start leuprolide 0.5 mg/day subcutaneously on cycle days 21-23 3
• Begin gonadotropin stimulation after achieving pituitary desensitization
• Advantage: Significantly lower cyst formation rate (~20% vs higher with follicular start) 2
• Outcome: Comparable pregnancy rates (21-25%) with standard protocols 3

Option 2: Combined Suppression Protocol (Most Effective for Cyst Prevention)

Add norethindrone acetate (NETA) to leuprolide for the first 8 days 4:

• Leuprolide acetate + NETA 5-10 mg daily for days 1-8
• This combination blocks the GnRH agonist flare response
• Results: Only 6.4% develop cysts >15 mm versus 25.9% with leuprolide alone (P<0.01) 4
• Estradiol levels remain suppressed (20.7 vs 57.3 pg/mL on day 8, P<0.01) 4
• No compromise in outcomes: Pregnancy rates (26.8% vs 22.6%) and delivery rates remain equivalent 4
• Cost-effective: Significantly reduces cycle cancellations and office visits

Option 3: Microdose Flare Protocol (For Poor Responders Only)

• Reserved for patients with elevated baseline FSH (≥15 mIU/mL) or previous poor response
• Start leuprolide at very low doses (40-50 mcg twice daily) in early follicular phase
• Rationale: Better pregnancy rates in poor responders (20.4% vs 11.7% with long protocol) 5
• Trade-off: Higher cyst risk but improved follicular recruitment in this specific population

Alternative: GnRH Antagonist Protocol

Consider switching to a GnRH antagonist protocol entirely to avoid the flare effect:

• No initial gonadotropin surge
• No cyst formation from agonist flare
• Flexible start timing
• Comparable pregnancy outcomes to long agonist protocols
• Particularly useful if patient has history of recurrent cyst formation with agonists

Key Clinical Pearls

Cyst Characteristics Matter:

• Luteal phase cysts: More benign, better prognosis after aspiration
• Follicular phase cysts: More problematic, associated with poorer outcomes
• Cyst fluid analysis shows normal steroid levels but no viable oocytes 2

Monitoring Strategy:

• Perform baseline ultrasound before starting gonadotropins
• If cysts >15 mm detected, aspirate before proceeding
• Check estradiol on day 8 of leuprolide—levels >50 pg/mL indicate inadequate suppression 4

Cost Considerations:

The NETA + leuprolide combination significantly reduces overall cycle costs by:

• Decreasing cancellation rates (from 25.9% to 6.4%) 4
• Reducing monitoring visits
• Preventing cycle delays

What NOT to Do

Do not cancel the cycle solely due to cyst presence—aspiration allows safe continuation 2. The evidence shows that systematic cyst aspiration permits proceeding with stimulation as scheduled without compromising outcomes.

Do not use GnRH agonists for ovarian protection during chemotherapy—this is a separate indication where evidence shows no protective benefit 6, though this is irrelevant to your IVF question.

Bottom Line Algorithm

1. Prevention first: Use luteal-phase start (days 21-23) + consider adding NETA for first 8 days
2. If cysts develop: Aspirate under local anesthesia and proceed with stimulation
3. If recurrent cysts: Switch to GnRH antagonist protocol for future cycles
4. For poor responders: Consider microdose flare protocol despite higher cyst risk, as benefits outweigh risks in this population

The combination of luteal-phase initiation with NETA co-treatment provides the most robust cyst prevention while maintaining excellent IVF outcomes 4.